Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β 2 -microglobulin yields a more accurate GELTAMO-IPI.

MLA

Montalbán, Carlos, et al. “Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL): The Addition of β 2 -Microglobulin Yields a More Accurate GELTAMO-IPI.” British Journal of Haematology, vol. 176, no. 6, Mar. 2017, pp. 918–28. EBSCOhost, https://doi.org/10.1111/bjh.14489.

APA

Montalbán, C., Díaz-López, A., Dlouhy, I., Rovira, J., Lopez-Guillermo, A., Alonso, S., Martín, A., Sancho, J. M., García, O., Sánchez, J. M., Rodríguez, M., Novelli, S., Salar, A., Gutiérrez, A., Rodríguez-Salazar, M. J., Bastos, M., Domínguez, J. F., Fernández, R., Gonzalez de Villambrosia, S., … García, J. F. (2017). Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β 2 -microglobulin yields a more accurate GELTAMO-IPI. British Journal of Haematology, 176(6), 918–928. https://doi.org/10.1111/bjh.14489

Chicago

Montalbán, Carlos, Antonio Díaz-López, Ivan Dlouhy, Jordina Rovira, Armando Lopez-Guillermo, Sara Alonso, Alejandro Martín, et al. 2017. “Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL): The Addition of β 2 -Microglobulin Yields a More Accurate GELTAMO-IPI.” British Journal of Haematology 176 (6): 918–28. doi:10.1111/bjh.14489.